Table 1.
Characteristics of study population (n=99 participants)
| Placebo (n = 63) | Oseltamivir (n = 36) | |
|---|---|---|
| Units |
9 (60%) |
6 (40%) |
|
Units in first season N (%) |
6 (67%) |
3 (50%) |
| No. (%) females |
39 (61.9%) |
26 (72.2%) |
| Mean age (years) (SD) |
79.1 (9.4) |
83.7 (8.4) |
| - Female |
81.6 (9.0) |
85.9 (5.9) |
| - Male |
75.0 (8.7) |
78.0 (11.4) |
| No (%) vaccinated |
|
|
| - 2011/2012 |
32 (76.2%) |
17 (100%) |
| - 2012/2013 |
19 (90.5%) |
19 (100%) |
| Total (%) |
51 (81.0%) |
36 (100%) |
| Side effects (n participants) |
2 |
5 |
| Discontinued (n participants) | 2 | 2 |